| Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes M Prabu-Jeyabalan, E Nalivaika, CA Schiffer Structure 10 (3), 369-381, 2002 | 431 | 2002 |
| Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor NM King, M Prabu-Jeyabalan, EA Nalivaika, P Wigerinck, MP de Béthune, ... Journal of virology 78 (21), 12012-12021, 2004 | 309 | 2004 |
| How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease M Prabu-Jeyabalan, E Nalivaika, CA Schiffer Journal of molecular biology 301 (5), 1207-1220, 2000 | 218 | 2000 |
| Combating susceptibility to drug resistance: lessons from HIV-1 protease NM King, M Prabu-Jeyabalan, EA Nalivaika, CA Schiffer Chemistry & biology 11 (10), 1333-1338, 2004 | 188 | 2004 |
| Molecular basis for drug resistance in HIV-1 protease A Ali, RM Bandaranayake, Y Cai, NM King, M Kolli, S Mittal, JF Murzycki, ... Viruses 2 (11), 2509, 2010 | 178 | 2010 |
| Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces SMD Shandilya, MNL Nalam, EA Nalivaika, PJ Gross, JC Valesano, ... Structure 18 (1), 28-38, 2010 | 154 | 2010 |
| Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy M Prabu-Jeyabalan, EA Nalivaika, NM King, CA Schiffer Journal of virology 77 (2), 1306-1315, 2003 | 137 | 2003 |
| Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease M Prabu-Jeyabalan, EA Nalivaika, NM King, CA Schiffer Journal of virology 78 (22), 12446-12454, 2004 | 129 | 2004 |
| Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease DA Ragland, EA Nalivaika, MNL Nalam, KL Prachanronarong, H Cao, ... Journal of the American Chemical Society 136 (34), 11956-11963, 2014 | 109 | 2014 |
| Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188 GJ Lockbaum, AC Reyes, JM Lee, R Tilvawala, EA Nalivaika, A Ali, ... Viruses 13 (2), 174, 2021 | 107 | 2021 |
| Extreme entropy–enthalpy compensation in a drug-resistant variant of HIV-1 protease NM King, M Prabu-Jeyabalan, RM Bandaranayake, MNL Nalam, ... ACS chemical biology 7 (9), 1536-1546, 2012 | 102 | 2012 |
| The ssDNA mutator APOBEC3A is regulated by cooperative dimerization MF Bohn, SMD Shandilya, TV Silvas, EA Nalivaika, T Kouno, BA Kelch, ... Structure 23 (5), 903-911, 2015 | 99 | 2015 |
| Lack of synergy for inhibitors targeting a multi‐drug‐resistant HIV‐1 protease NM King, L Melnick, M Prabu‐Jeyabalan, EA Nalivaika, SS Yang, Y Gao, ... Protein Science 11 (2), 418-429, 2002 | 99 | 2002 |
| Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate M Prabu-Jeyabalan, EA Nalivaika, K Romano, CA Schiffer Journal of virology 80 (7), 3607-3616, 2006 | 79 | 2006 |
| Asn177 in Escherichia coli thymidylate synthase is a major determinant of pyrimidine specificity. LW Hardy, E Nalivaika Proceedings of the National Academy of Sciences 89 (20), 9725-9729, 1992 | 71 | 1992 |
| Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions TV Silvas, S Hou, W Myint, E Nalivaika, M Somasundaran, BA Kelch, ... Scientific reports 8 (1), 7511, 2018 | 60 | 2018 |
| Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV‐1 protease MD Altman, EA Nalivaika, M Prabu‐Jeyabalan, CA Schiffer, B Tidor Proteins: Structure, Function, and Bioinformatics 70 (3), 678-694, 2008 | 58 | 2008 |
| Drug design strategies to avoid resistance in direct-acting antivirals and beyond AN Matthew, F Leidner, GJ Lockbaum, M Henes, J Zephyr, S Hou, ... Chemical reviews 121 (6), 3238-3270, 2021 | 51 | 2021 |
| The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways RM Bandaranayake, M Kolli, NM King, EA Nalivaika, A Heroux, ... Journal of virology 84 (19), 9995-10003, 2010 | 50 | 2010 |
| Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease M Prabu-Jeyabalan, NM King, EA Nalivaika, G Heilek-Snyder, ... Antimicrobial agents and chemotherapy 50 (4), 1518-1521, 2006 | 45 | 2006 |
